Robert A. Ramirez

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

Open-label Phase 2, Hepatology, Medicine +8

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Bruno Bockorny, Valerya Semenisty, Teresa Macarulla et al. · Nature Medicine · 2020 · 501 citations

Cxcr4 Antagonist, Oncology, Pancreatic Cancer +8

Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly et al. · Journal of Clinical Oncology · 2022 · 120 citations · Full text

Incomplete Intrapulmonary Lymph Node Retrieval After Routine Pathologic Examination of Resected Lung Cancer

Robert A. Ramirez, Christopher G. Wang, Laura E. Miller et al. · Journal of Clinical Oncology · 2012 · 112 citations

The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors

Robert A. Ramirez, David T. Beyer, Aman Chauhan et al. · The Oncologist · 2016 · 95 citations · Full text